SCHEMBL26569856

SCHEMBL26569856

CC(C)(C)c1cccc(OS(=O)(=O)F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOD1 P00441 1/20 0.43
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
CA1 P00915 3/20 0.41
CA2 P00918 3/20 0.41
CA9 Q16790 3/20 0.41
ACHE P22303 3/20 0.41
HDAC4 P56524 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
HTT P42858 1/20 0.39
ELANE P08246 1/20 0.38
ALDH1A1 P00352 3/20 0.37
NPC1 O15118 1/20 0.37
PLA2G1B P04054 1/20 0.37
NFKB1 P19838 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2349455 0.84 ACHE (0.44) SOD1CYP3A4CYP2C9CYP2C19CA1
SCHEMBL2980656 0.84 ALDH1A1 (0.51) SOD1CYP3A4CYP2C9CYP2C19CA1
SCHEMBL15685014 0.84 KDM4E (0.45) CA1CA2CA9L3MBTL1POLB
SCHEMBL26571369 0.83 NPC1 (0.43) SOD1CYP2C9CA1CA2CA9
SCHEMBL9451441 0.82 CA2 (0.66) CA1CA2CA9HDAC4HDAC2
SCHEMBL2980637 0.81 SOD1 (0.46) SOD1CYP3A4CYP2C9CYP2C19CA1
SCHEMBL18507891 0.80 CA1 (0.60) CA1CA2CA9ELANE
SCHEMBL7766026 0.79 MEN1 (0.45) SOD1CYP3A4CYP2C9CYP2C19CA1
SCHEMBL2978101 0.78 ALDH1A1 (0.51) CYP3A4CYP2C9CYP2C19L3MBTL1LMNA
SCHEMBL22719662 0.78 KIF11 (0.49) CYP2C9CYP2C19CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230331721-A1 POTENT AND SELECTIVE COVALENT INHIBITORS OF SERINE-ARGININE PROTEIN KINASE (SRPK) 1 AND SRPK2 AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-10-19 US disclosed
US-20230331721-A1 POTENT AND SELECTIVE COVALENT INHIBITORS OF SERINE-ARGININE PROTEIN KINASE (SRPK) 1 AND SRPK2 AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331721-A1 POTENT AND SELECTIVE COVALENT INHIBITORS OF SERINE-ARGININE PROTEIN KINASE (SRPK) 1 AND SRPK2 AND USES THEREOF SRPK1, SRPK2, SRPK3 SOD1 2194/4885CYP3A4 4785/4885CYP2C9 4779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.